Opioid use has reached crisis proportions not only in the United States but also in Canada and some European countries, as prescription opioid painkillers have become much more common, the OECD club of wealthy nations said.
England’s National Health Service reached a deal to pay for U.S. drugmaker Biogen Inc.’s expensive spinal muscle atrophy treatment Spinraza.
Novartis’ Kymriah won the blessing of health authorities in England for adult lymphoma patients, the Swiss drugmaker said, reversing the 2018 rejection of the cell therapy.
A new report indicates that the so-called “Brexit” will have a negative impact on healthcare in the United Kingdom.
According to a drug shortage list provided by the U.S. Food and Drug Administration, there have been more than 100 drugs that have faced shortages during 2018.
Novartis will cut 2,550 jobs in Switzerland and Britain over four years as the Swiss drugmaker strives to boost profits and focus on new medicines.
Ashfield Healthcare Communications is set to expand its business further by opening an office in the heart of Manchester, UK.
AstraZeneca is increasing stockpiles of those medicines in Britain and Europe that could be affected by Brexit by around 20 percent, in preparation for potential disruption if the UK crashes out of the EU without a deal.
Bayer is weighing legal action and Novartis has expressed concern at plans by doctors in the north of England to defy official guidance by using a cancer medicine as a cheap eye drug.
The British government has rekindled its industrial strategy, unveiled earlier in 2017 to prepare the economy for Brexit, with plans to boost the country’s pharmaceuticals sector via fresh investments and public-private collaborations.